TickerGuard
Buy Day today: Neutral (53) Mixed market breadth · no major macro event

Arcus Biosciences Inc (RCUS)

Healthcare Biotechnology
28.20 $
-0.2% vs. previous close
Closing price · As of: 31. Jul 2026

Who owns Arcus Biosciences Inc (RCUS)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 70.7% of the shares are freely tradable; institutional investors hold 72.4%.

Ownership Structure

Institutional ownership
72.4%
Insiders
29.2%
Float
70.7%
Short % of float
16.4%
Shares Outstanding
126Mio.

Largest Shareholders

Institutions

Institutions RCUS
Name Stake (%) Shares Change (%) Date
BlackRock Inc 12.11 15,226,475 +1.5 03/31/2026
Wellington Management Company LLP 4.84 6,089,516 +17.5 03/31/2026
State Street Corp 4.30 5,412,901 +18.3 03/31/2026
Suvretta Capital Management, LLC 4.00 5,030,993 -3.0 03/31/2026
Vanguard Portfolio Management, LLC 3.40 4,272,056 +0.0 03/31/2026
Vanguard Capital Management, LLC 3.07 3,856,725 +0.0 03/31/2026
Woodline Partners LP 3.00 3,777,798 +0.2 03/31/2026
Marshall Wace Asset Management Ltd 2.99 3,761,437 +11.0 03/31/2026

Funds

Funds RCUS
Name Stake (%) Shares Change (%) Date
iShares Core S&P Small-Cap ETF 4.21 5,293,950 +0.0 07/28/2026
Vanguard Health Care Inv 3.28 4,124,859 +28.7 03/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Insider Transactions

Insider Transactions
Date Person Role Type Shares Price Value
10. Jul 2026 Jaen Juan C. President Sell 268 29.40 7,878
10. Jul 2026 Jaen Juan C. President Sell 19,799 28.61 566,410
9. Jul 2026 Jaen Juan C. President Sell 48,502 30.05 1,457,631

Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.

View all insider transactions →

Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?